|
Re: Apropos AGM
|
4
|
Resverlogix Corp.
|
Jun 08, 2022 06:27PM
|
|
Re: Hope never dies....
|
4
|
Resverlogix Corp.
|
Jun 06, 2021 10:37AM
|
|
Re: And there's the news, 3 month loan extension....
|
4
|
Resverlogix Corp.
|
May 04, 2019 02:14PM
|
|
Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
|
4
|
Zenith Epigenetics
|
May 12, 2022 01:13PM
|
|
Re: Rock Stars still rocking it
|
4
|
Zenith Epigenetics
|
Jun 13, 2018 03:45PM
|
|
Re: ZCC relationship to ZEL!
|
4
|
Zenith Epigenetics
|
Apr 13, 2019 01:53PM
|
|
Zenith Financials
|
4
|
Zenith Epigenetics
|
Aug 31, 2017 12:59PM
|
|
Acerta Pharma BV
|
4
|
Resverlogix Corp.
|
Mar 20, 2016 12:02PM
|
|
Re: Concerns Mount Over COVID-19 'Rebounds' After Treatment With Pfizer's Paxlovid
|
4
|
Resverlogix Corp.
|
Jun 02, 2022 12:25PM
|
|
RVX continuous good news
|
4
|
Resverlogix Corp.
|
Jun 01, 2015 02:31PM
|
|
Re: More options exercised, this time by Ewelina Kulikowski
|
4
|
Resverlogix Corp.
|
Jul 13, 2018 01:14PM
|
|
Re: Optimistic
|
4
|
Resverlogix Corp.
|
Oct 18, 2021 06:54PM
|
|
Re: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
|
4
|
Resverlogix Corp.
|
May 15, 2017 05:17PM
|
|
Re: Great Presentation
|
4
|
Resverlogix Corp.
|
Nov 18, 2019 10:21AM
|
|
Re: Epigenetics: an exciting new approach in prostate cancer
|
4
|
Zenith Epigenetics
|
Apr 09, 2019 03:27PM
|
|
Re: COVID-19 and BRD4: a stormy and cardiotoxic bromo-romance
|
4
|
Resverlogix Corp.
|
Dec 14, 2021 12:30PM
|
|
Re: Why are you invested in RVX
|
4
|
Resverlogix Corp.
|
Jun 19, 2019 12:46PM
|
|
For perspective
|
4
|
Resverlogix Corp.
|
May 19, 2022 02:22PM
|
|
Classifying/taxonomy mCRPC patients
|
4
|
Zenith Epigenetics
|
Apr 20, 2019 02:12PM
|
|
Re: Another country listed on EU Clinical Trial Register for BETonMACE
|
4
|
Resverlogix Corp.
|
Dec 09, 2015 03:32PM
|
